Found 39 clinical trials
Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma
advanced or metastatic leiomyosarcoma who are inoperable are enrolled, aiming at the effectiveness and safety of temozolomide for injection combined with epirubicin as the first-line treatment for advanced
- 0 views
- 24 Mar, 2022
- 1 location
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
The primary objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of unesbulin in combination with dacarbazine for the treatment of advanced LMS and determine the overall safety profile of unesbulin in combination with dacarbazine. This study will employ the time-to-event …
- 14 views
- 11 May, 2022
- 4 locations
A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma
Multi-center, open-label, Phase I/II dose escalation and expansion trial of TTI-621 in patients with unresectable or metastatic high-grade leiomyosarcoma.
- 14 views
- 16 Jun, 2022
- 9 locations
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)
Dinutuximab beta was designed to bind to neuroblastoma cells and other cancer cells that express the GD2 antigen, such as STS/LMS cells, and it is believed that this binding "labels" the cells an makes them a better target. In addition, γδ T cells can safely be expanded in-vivo using intravenous …
- 0 views
- 20 Jun, 2022
- 2 locations
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
This phase II trial studies how well cabozantinib and temozolomide work in treating patients with leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery (unresectable) or
- 0 views
- 11 Nov, 2021
- 7 locations
Targeting ATR in Soft-tissue Sarcomas (TARSARC)
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of berzosertib in association with gemcitabine
- 0 views
- 18 Apr, 2022
- 1 location
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (FIBROSARC US)
leiomyosarcoma patients.
- 0 views
- 06 May, 2022
- 8 locations
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS)
with retroperitoneal and resectable soft tissue sarcoma (liposarcoma and leiomyosarcoma) Phase I: escalating dose of 1.3 or 1.5 mg/m2. Phase I for cohort C: de-escalating dose of 1.5 or 1.3mg/m2
- 25 views
- 17 Jun, 2022
- 13 locations
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia)
In this phase 2 clinical trial, the aim is to evaluate the efficacy of the ER-antagonist Fulvestrant in women with estrogen receptor positive (ER+) low grade gynecological cancers. The primary objective of the study is to determine the response rate (RR) upon Fulvestrant treatment, comprising either partial or complete response, …
- 24 views
- 03 Feb, 2022
- 1 location
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
Phase I-II, randomized, open-label, multicenter, international clinical trial Patients with advanced soft-tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, alveolar soft-part
- 0 views
- 25 Nov, 2021
- 7 locations